Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clinical Genomics Laboratory, |
RCV004598553 | SCV005091105 | pathogenic | Hypercholesterolemia, familial, 1 | 2022-01-20 | criteria provided, single submitter | clinical testing | This deletion includes exons 1-6 of the LDLR gene. The breakpoints of this event extend beyond the interrogated LDLR region, but additional RefSeq genes are not included in the deletion. Overlapping and similar-sized deletions involving exons 1-6 of the LDLR gene have been previously reported in at least 4 individuals with familial hypercholesterolemia or homozygous familial hypercholesterolemia (Lelli et al., 1991; Sun et al., 1992; Bertolini et al., 2000; Awan et al., 2008). Deletion involving the LDLR gene partially overlapping the deletion identified here has been identified in 2/1, 936 East Asian chromosomes (2/20,002 chromosomes overall) by the Genome Aggregation Database (http://gnomad.broadinstitute.org/). Although overlapping deletions have been seen in the general population, their frequency is low enough to be consistent with the prevalence of familial hypercholesterolemia. This deletion removes 6 out of 18 exons of the LDLR gene and is expected to result in a truncated or absent protein product. Loss-of-function is an established mechanism of disease for the LDLR gene. These data were assessed using the ACMG/ClinGen copy number variant interpretation guidelines. In summary, there is sufficient evidence to classify the LDLR exons 1-6 deletion as pathogenic for familial hypercholesterolemia in an autosomal dominant manner based on the information above. |